Download Presentazione di PowerPoint

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

page
1
page
2
page
3
page
4
page
5
page
6
page
7
page
8
page
9
page
10
page
11
Document related concepts
no text concepts found
Transcript 
Becker RC, et al. Lancet 2009;373:919-28
SCH 530348
Becker RC, et al. Lancet 2009;373:919-28
Study profile
Becker RC, et al. Lancet 2009;373:919-28
Baseline characteristics and
concomitant medication use
Becker RC, et al. Lancet 2009;373:919-28
Rate of bleeding events in the primary
percutaneous coronary intervention cohort
over 60 days of maintenance therapy
Becker RC, et al. Lancet 2009;373:919-28
Major secondary efficacy outcomes for
primary percutaneous coronary intervention
cohort over 60 days of maintenance therapy
Becker RC, et al. Lancet 2009;373:919-28
Rates (95% CI) of thrombolysis in myocardial
infarction (TIMI) major and minor bleeding versus
death or major adverse cardiac effects (MACE)
Becker RC, et al. Lancet 2009;373:919-28
Safety outcomes in patients receiving study drug who
subsequently needed coronary artery bypass grafting
Becker RC, et al. Lancet 2009;373:919-28
Rate of bleeding events during 60 days of maintenance
therapy in the secondary non-percutaneous coronary
intervention cohort (treated medically)
Becker RC, et al. Lancet 2009;373:919-28
Proportion of patients with at least 80%
inhibition of thrombin receptor agonist peptide
(TRAP)-induced platelet aggregation
Becker RC, et al. Lancet 2009;373:919-28
Proportion of patients with at least 80% inhibition of
thrombin receptor agonist peptide (TRAP)-induced
platelet aggregation at 30 days and 60 days
Becker RC, et al. Lancet 2009;373:919-28
Related documents